OliX Pharmaceuticals Raises KRW 110 Billion in Strategic Investment from L’Oréal’s BOLD and Weiss Asset Management OliX Pharmaceuticals, Inc., a leading biotechnology company specializing in RNA interference (RNAi) therapeutics, has announced the successful raising of approximately KRW 110 billion through…
Rezon Bio Appoints Dr. Ralf Otto as Chief Operating Officer to Strengthen Global CDMO Expansion Strategy Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), has announced the appointment of Dr. Ralf Otto, PhD, as its new…
Natera Appoints Oncology Leaders Thomas Lynch and Eric Rubin to Board of Directors to Strengthen Precision Medicine Strategy Natera, Inc., a global leader in cell-free DNA testing and precision medicine diagnostics, has announced the appointment of two highly regarded oncology…
Alliance Clinical Network and Atlas Clinical Research Complete Merger to Create Expanded National Clinical Research Platform Alliance Clinical Network and Atlas Clinical Research have announced the successful completion of a strategic merger, creating an expanded clinical research organization with nearly…
Avenzo Reports Updated Phase 1 Data for AVZO-021 Showing Clinical Activity and Favorable Tolerability in Heavily Pretreated HR+/HER2- Breast Cancer Avenzo Therapeutics has announced updated clinical findings from the Phase 1 portion of its ongoing Phase 1/2 clinical study evaluating…
Beren Therapeutics to Present Comprehensive Adrabetadex Data at 2026 NPC Research Conference, Highlighting Early Treatment Benefits and Mechanistic Insights Beren Therapeutics P.B.C., the parent company of Mandos LLC and a biotechnology company focused on cholesterol trafficking biology and cyclodextrin-based therapeutic…
PanTher Therapeutics Advances PTM-101 with Phase 1b Dose Escalation Completion in Pancreatic Cancer and Appoints Oncology Veteran Tim Clackson to Board PanTher Therapeutics, a clinical-stage biotechnology company developing implant-based localized cancer therapies, has announced a key clinical and corporate milestone…
Secretome Therapeutics Secures $30 Million Series A Financing Led by RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathy Secretome Therapeutics has announced the successful completion of a $30 million Series A financing round led exclusively by RA Capital Management,…
LINZESS® (linaclotide) Receives FDA Approval for Children Aged 2 and Older with Functional Constipation Ironwood Pharmaceuticals has announced that the U.S. Food and Drug Administration has approved an expanded indication for LINZESS, allowing the treatment to be used in pediatric…
Verastem Oncology Names Michael P. Bailey to Board of Directors Verastem Oncology has announced the appointment of veteran biotechnology executive Michael P. Bailey to its Board of Directors, strengthening the company’s leadership team as it advances a growing portfolio of…
Datroway Gains Landmark U.S. Approval for First-Line Treatment of Metastatic Triple-Negative Breast Cancer In a major advancement for breast cancer treatment, Daiichi Sankyo and AstraZeneca have announced that the U.S. Food and Drug Administration (FDA) has approved Datroway® (datopotamab deruxtecan-dlnk)…
Henry Schein Appoints Dan Daniel as Independent Chairman Following Stanley Bergman’s Retirement Henry Schein has announced a major leadership transition as its Board of Directors elected William K. “Dan” Daniel to serve as Independent Chairman of the Board, effective May…